ClinicalTrials.gg
TerminatedNCT04564339SANCTUARYUpdated Jan 22, 2026Results posted

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

A Phase 2 interventional study of Ravulizumab and Placebo in Lupus Nephritis and Immunoglobulin A Nephropathy, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 64 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
28th of 100
123 · median 50
Started
2021
with 1 other
Phase 2
34 of 114
7 open now
Registered
51st of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 28th largest by enrollment of the 100 interventional ones that give a count, is one of 2 that started in 2021, is one of 34 in phase 2, and was the 51st registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).

Read the detailed description

This study consists of a 6-week Screening Period, 26-week Initial Evaluation Period, a 24-week Extension Period, and a 36-week post-treatment Follow-up Period.

03

Conditions studied

  • Lupus Nephritis
  • Immunoglobulin A Nephropathy

Keywords

  • glomerulonephritis
  • IGA
  • lupus nephritis
  • complement C5
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Common to both disease cohorts:

  • Proteinuria ≥1 (gram [g]/day or g/g)
  • Vaccinated against meningococcal infection
  • Vaccinated for Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae according to national/local regulatory requirements

For LN cohort:

  • Diagnosis of active focal or diffuse proliferative LN Class III or IV
  • Clinically active LN, requiring/receiving induction treatment

For IgAN cohort:

  • Diagnosis of primary IgAN
  • Compliance with stable and optimal dose of renin-angiotensin system inhibitor treatment for ≥ 3 months

Exclusion criteria

Exclusion Criteria:

Common to both disease cohorts:

  • \< 30 milliliters/minute/1.73 meters squared
  • Previously received a complement inhibitor (for example, eculizumab)
  • Concomitant significant renal disease other than LN or IgAN
  • History of other solid organ or bone marrow transplant
  • Uncontrolled hypertension

For IgAN cohort:

  • Diagnosis of rapid progressive glomerulonephritis
  • Prednisone or prednisone equivalent > 20 milligram (mg) per day for > 14 consecutive days or any other within 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Ravulizumab: LN Cohort

    Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.

    Drug: Ravulizumab · Other: Background Therapy

  • Placebo comparator
    Placebo: LN Cohort

    Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.

    Drug: Placebo · Other: Background Therapy

  • Experimental
    Ravulizumab: IgAN Cohort

    Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.

    Drug: Ravulizumab · Other: Background Therapy

  • Placebo comparator
    Placebo: IgAN Cohort

    Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.

    Drug: Ravulizumab · Drug: Placebo · Other: Background Therapy

Interventions

  • Dosages (loading and maintenance) will be based on the participant's body weight.

    Also known as: Ultomiris

  • DrugPlacebo

    Dosages (loading and maintenance) will be based on the participant's body weight.

  • OtherBackground Therapy

    Participants will receive background therapy consistent with the standard of care.

06

What researchers measure

Primary outcomes

  1. IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections)

    Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

    Time frame: Baseline, Week 26

  2. LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections)

    Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections)

    Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

    Time frame: Baseline, Week 50

  2. LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections)

    Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

    Time frame: Baseline, Week 50

  3. IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections

    Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints.

    Time frame: Baseline to Week 26 and Week 50

  4. LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections

    Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints.

    Time frame: Baseline to Week 26 and Week 50

  5. IgAN Cohort: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 50

    Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in milliliters/minute/1.73 meters squared (mL/min/1.73 m\^2). Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.

    Time frame: Baseline, Week 26 and Week 50

  6. LN Cohort: Change From Baseline in eGFR at Week 26 and Week 50

    Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in mL/min/1.73 m\^2. Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.

    Time frame: Baseline, Week 26 and Week 50

  7. IgAN Cohort: Change From Baseline in Serum Complement Component 3 (C3) and Complement Component 4 (C4) Concentrations at Week 26 and Week 50

    Time frame: Baseline, Week 26 and Week 50

  8. LN Cohort: Change From Baseline in Serum C3 and C4 Concentrations at Week 26 and Week 50

    Time frame: Baseline, Week 26 and Week 50

  9. LN Cohort: Percentage of Participants Meeting the Criteria for Complete Renal Response (CRR)

    The CRR was defined as meeting all 3 of the following criteria: - UPCR ≤0.5 gram/gram (g/g); - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal systemic lupus erythematosus (SLE) flare, or suboptimal response.

    Time frame: Week 26 and Week 50

  10. LN Cohort: Percentage of Participants Meeting the Criteria for Partial Renal Response (PRR)

    The PRR was defined as meeting all 3 of the following criteria: - decrease of UPCR \>50% from baseline; - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.

    Time frame: Week 26 and Week 50

  11. LN Cohort: Time to Urine Protein to Creatinine Ratio (UPCR) < 0.5 g/g, as Measured by Spot Urine Samples

    Time frame: Baseline through Week 50

  12. LN Cohort: Percentage of Participants Achieving Corticosteroid Taper to 7.5 Milligrams (mg)/Day

    A corticosteroid taper was carried out per protocol at the clinical discretion of the investigator.

    Time frame: Week 14, Week 26, and Week 50

  13. LN Cohort: Percentage of Participants With Renal Flare

    Renal flare was determined in the opinion of the investigator and additional protocol-specified criteria. For participants who achieved a CRR, a renal flare was the reproducible recurrence of proteinuria ≥1g/g. For all other participants, a renal flare was either of the following: a reproducible increase of serum creatinine \>25% higher than baseline, above the upper limit of normal (plus additional protocol-specified criteria), or a reproducible doubling of the UPCR from a 24-hour urine collection compared with the lowest previous value obtained after the first dose of study intervention.

    Time frame: Baseline through Week 50

  14. LN Cohort: Percentage of Participants With Extrarenal Systemic Lupus Erythematosus (SLE) Flare

    Extrarenal SLE flare was defined as an increase in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Safety of Estrogens in Lupus Erythematosus National Assessment modification ≥4 points that was not accounted for by proteinuria, hematuria, urinary cellular casts, hypocomplementemia, or an increase in anti-double-stranded DNA antibody level. The SLEDAI-2K is an instrument that was used to assess the disease activity of extrarenal SLE flare across 18 disease descriptors. Each descriptor carried a weighted value ranging from 1-8, with the reported score calculated as the sum of these descriptors and ranging from 0 to 85. Higher scores represent increased degrees of disease activity.

    Time frame: Baseline through Week 50

  15. LN Cohort: Percentage of Participants With Treatment Failure

    Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.

    Time frame: Baseline through Week 50

  16. LN Cohort: Percentage of Participants With Suboptimal Response

    A suboptimal response was to be determined in the opinion of the investigator in addition to the following criterion: reproducible proteinuria ≤25% decreased compared to baseline based on UPCR on a 24-hour urine collection performed by a central laboratory.

    Time frame: Baseline through Week 50

  17. LN Cohort: Change From Baseline in Serum Albumin at Week 26 and Week 50

    For the determination of serum albumin, blood samples were obtained at designated time points.

    Time frame: Baseline, Week 26, Week 50

  18. IgAN Cohort: Percentage of Participants Meeting the Criteria for Partial Remission

    Partial remission was defined as mean proteinuria \<1 g/24 hours, based on two valid 24-hour urine collections obtained within 2 weeks prior to the study visit.

    Time frame: Week 26 and Week 50

07

Results

Posted Jan 22, 2026
Limitations and caveats
The LN cohort of the study was terminated early due to lack of efficacy.

Participant flow

Initial Evaluation Period (26 Weeks)
Participant flow — Initial Evaluation Period (26 Weeks)
MilestoneLN Cohort: RavulizumabLN Cohort: PlaceboIgAN Cohort: RavulizumabIgAN Cohort: Placebo
Started38194323
Received at least 1 dose of study drug38194323
Completed36184223
Not completed2110
Withdrew: Withdrawal by subject1110
Withdrew: Physician decision1000
Extension Period (Week 26 to Week 50)
Participant flow — Extension Period (Week 26 to Week 50)
MilestoneLN Cohort: RavulizumabLN Cohort: PlaceboIgAN Cohort: RavulizumabIgAN Cohort: Placebo
Started36184223
Completed34174123
Not completed2110
Withdrew: Physician decision1010
Withdrew: Withdrawal by subject1000
Withdrew: Study terminated by sponsor0100

Outcome measures

PrimaryIgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections)

Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

Time frame:
Baseline, Week 26
Reported as:
Geometric least squares mean · percentage change
IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections)
percentage changeIgAN Cohort: RavulizumabIgAN Cohort: Placebo
IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections)-41.9 (-50.2 to -32.0)-16.8 (-31.8 to 1.6)
Statistical analysis
  • IgAN Cohort: Ravulizumab vs IgAN Cohort: Placebo · ANCOVA · p = 0.0053 · Percentage difference: -30.1 · 90% CI -43.5 to -13.7
PrimaryLN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections)

Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

Time frame:
Baseline, Week 26
Reported as:
Geometric least squares mean · percentage change
LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections)
percentage changeLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections)-69.7 (-79.9 to -54.5)-67.0 (-80.8 to -43.1)
Statistical analysis
  • LN Cohort: Ravulizumab vs LN Cohort: Placebo · ANCOVA · p = 0.8036 · Percentage difference: -8.4 · 90% CI -48.6 to 63.2
SecondaryIgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections)

Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

Time frame:
Baseline, Week 50
Reported as:
Geometric least squares mean · percentage change
IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections)
percentage changeIgAN Cohort - RavulizumabIgAN Cohort - Placebo
IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections)-44.8 (-55.1 to -32.1)-45.1 (-58.0 to -28.4)
SecondaryLN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections)

Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.

Time frame:
Baseline, Week 50
Reported as:
Geometric least squares mean · percentage change
LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections)
percentage changeLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections)-77.1 (-86.0 to -62.4)-75.0 (-87.2 to -51.2)
SecondaryIgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections

Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints.

Time frame:
Baseline to Week 26 and Week 50
Reported as:
Number · percentage of participants
IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections
percentage of participantsIgAN Cohort: RavulizumabIgAN Cohort: Placebo
Week 26: >30% Reduction68.3 (51.9 to 81.9)40.9 (20.7 to 63.6)
Week 26: >50% Reduction43.9 (28.5 to 60.3)18.2 (5.2 to 40.3)
Week 50: >30% Reduction63.4 (46.9 to 77.9)60.9 (38.5 to 80.3)
Week 50: >50% Reduction36.6 (22.1 to 53.1)39.1 (19.7 to 61.5)
SecondaryLN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections

Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints.

Time frame:
Baseline to Week 26 and Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
Week 26: >30% Reduction50.0 (33.4 to 66.6)73.7 (48.8 to 90.9)
Week 26: >50% Reduction47.4 (31.0 to 64.2)57.9 (33.5 to 79.7)
Week 50: >30% Reduction55.3 (38.3 to 71.4)63.2 (38.4 to 83.7)
Week 50: >50% Reduction52.6 (35.8 to 69.0)47.4 (24.4 to 71.1)
SecondaryIgAN Cohort: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 50

Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in milliliters/minute/1.73 meters squared (mL/min/1.73 m\^2). Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.

Time frame:
Baseline, Week 26 and Week 50
Reported as:
Least squares mean · mL/min/1.73 m^2
IgAN Cohort: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 50
mL/min/1.73 m^2IgAN Cohort: RavulizumabIgAN Cohort: Placebo
Change at Week 260.22 (-2.30 to 2.74)-4.51 (-7.90 to -1.11)
Change at Week 50-3.87 (-6.41 to -1.33)-6.33 (-9.72 to -2.94)
SecondaryLN Cohort: Change From Baseline in eGFR at Week 26 and Week 50

Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in mL/min/1.73 m\^2. Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.

Time frame:
Baseline, Week 26 and Week 50
Reported as:
Least squares mean · mL/min/1.73 m^2
LN Cohort: Change From Baseline in eGFR at Week 26 and Week 50
mL/min/1.73 m^2LN Cohort: RavulizumabLN Cohort: Placebo
Change at Week 2611.59 ± 3.3814.04 ± 4.56
Change at Week 5012.12 ± 3.4914.83 ± 4.86
SecondaryIgAN Cohort: Change From Baseline in Serum Complement Component 3 (C3) and Complement Component 4 (C4) Concentrations at Week 26 and Week 50
Time frame:
Baseline, Week 26 and Week 50
Reported as:
Mean · grams/liter
IgAN Cohort: Change From Baseline in Serum Complement Component 3 (C3) and Complement Component 4 (C4) Concentrations at Week 26 and Week 50
grams/literIgAN Cohort: RavulizumabIgAN Cohort: Placebo
C3: Change at Week 260.027 ± 0.2389-0.019 ± 0.2366
C3: Change at Week 50-0.001 ± 0.1902-0.084 ± 0.1861
C4: Change at Week 26-0.005 ± 0.0576-0.001 ± 0.0566
C4: Change at Week 50-0.006 ± 0.0510-0.027 ± 0.0489
SecondaryLN Cohort: Change From Baseline in Serum C3 and C4 Concentrations at Week 26 and Week 50
Time frame:
Baseline, Week 26 and Week 50
Reported as:
Least squares mean · grams/liter
LN Cohort: Change From Baseline in Serum C3 and C4 Concentrations at Week 26 and Week 50
grams/literLN Cohort: RavulizumabLN Cohort: Placebo
C3: Change at Week 260.139 ± 0.24140.130 ± 0.1809
C3: Change at Week 500.213 ± 0.47830.247 ± 0.2703
C4: Change at Week 260.041 ± 0.07750.028 ± 0.0668
C4: Change at Week 500.042 ± 0.08870.052 ± 0.0891
SecondaryLN Cohort: Percentage of Participants Meeting the Criteria for Complete Renal Response (CRR)

The CRR was defined as meeting all 3 of the following criteria: - UPCR ≤0.5 gram/gram (g/g); - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal systemic lupus erythematosus (SLE) flare, or suboptimal response.

Time frame:
Week 26 and Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants Meeting the Criteria for Complete Renal Response (CRR)
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
Week 2626.3 (13.4 to 43.1)21.1 (6.1 to 45.6)
Week 5042.1 (26.3 to 59.2)31.6 (12.6 to 56.6)
SecondaryLN Cohort: Percentage of Participants Meeting the Criteria for Partial Renal Response (PRR)

The PRR was defined as meeting all 3 of the following criteria: - decrease of UPCR \>50% from baseline; - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.

Time frame:
Week 26 and Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants Meeting the Criteria for Partial Renal Response (PRR)
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
Week 2615.8 (6.0 to 31.3)36.8 (16.3 to 61.6)
Week 5010.5 (2.9 to 24.8)10.5 (1.3 to 33.1)
SecondaryLN Cohort: Time to Urine Protein to Creatinine Ratio (UPCR) < 0.5 g/g, as Measured by Spot Urine Samples
Time frame:
Baseline through Week 50
Reported as:
Median · days
LN Cohort: Time to Urine Protein to Creatinine Ratio (UPCR) < 0.5 g/g, as Measured by Spot Urine Samples
daysLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Time to Urine Protein to Creatinine Ratio (UPCR) < 0.5 g/g, as Measured by Spot Urine Samples184.0 (71.0 to NA)295.0 (128.0 to NA)
SecondaryLN Cohort: Percentage of Participants Achieving Corticosteroid Taper to 7.5 Milligrams (mg)/Day

A corticosteroid taper was carried out per protocol at the clinical discretion of the investigator.

Time frame:
Week 14, Week 26, and Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants Achieving Corticosteroid Taper to 7.5 Milligrams (mg)/Day
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
Week 1484.2 (68.7 to 94.0)94.4 (72.7 to 99.9)
Week 2694.4 (81.3 to 99.3)100 (81.5 to 100)
Week 5076.5 (58.8 to 89.3)82.4 (56.6 to 96.2)
SecondaryLN Cohort: Percentage of Participants With Renal Flare

Renal flare was determined in the opinion of the investigator and additional protocol-specified criteria. For participants who achieved a CRR, a renal flare was the reproducible recurrence of proteinuria ≥1g/g. For all other participants, a renal flare was either of the following: a reproducible increase of serum creatinine \>25% higher than baseline, above the upper limit of normal (plus additional protocol-specified criteria), or a reproducible doubling of the UPCR from a 24-hour urine collection compared with the lowest previous value obtained after the first dose of study intervention.

Time frame:
Baseline through Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants With Renal Flare
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Percentage of Participants With Renal Flare13.2 (4.4 to 28.1)5.3 (0.1 to 26.0)
SecondaryLN Cohort: Percentage of Participants With Extrarenal Systemic Lupus Erythematosus (SLE) Flare

Extrarenal SLE flare was defined as an increase in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Safety of Estrogens in Lupus Erythematosus National Assessment modification ≥4 points that was not accounted for by proteinuria, hematuria, urinary cellular casts, hypocomplementemia, or an increase in anti-double-stranded DNA antibody level. The SLEDAI-2K is an instrument that was used to assess the disease activity of extrarenal SLE flare across 18 disease descriptors. Each descriptor carried a weighted value ranging from 1-8, with the reported score calculated as the sum of these descriptors and ranging from 0 to 85. Higher scores represent increased degrees of disease activity.

Time frame:
Baseline through Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants With Extrarenal Systemic Lupus Erythematosus (SLE) Flare
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Percentage of Participants With Extrarenal Systemic Lupus Erythematosus (SLE) Flare2.6 (0.1 to 13.8)0.0 (0.0 to 17.6)
SecondaryLN Cohort: Percentage of Participants With Treatment Failure

Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.

Time frame:
Baseline through Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants With Treatment Failure
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Percentage of Participants With Treatment Failure26.3 (13.4 to 43.1)10.5 (1.3 to 33.1)
SecondaryLN Cohort: Percentage of Participants With Suboptimal Response

A suboptimal response was to be determined in the opinion of the investigator in addition to the following criterion: reproducible proteinuria ≤25% decreased compared to baseline based on UPCR on a 24-hour urine collection performed by a central laboratory.

Time frame:
Baseline through Week 50
Reported as:
Number · percentage of participants
LN Cohort: Percentage of Participants With Suboptimal Response
percentage of participantsLN Cohort: RavulizumabLN Cohort: Placebo
LN Cohort: Percentage of Participants With Suboptimal Response7.9 (1.7 to 21.4)10.5 (1.3 to 33.1)
SecondaryLN Cohort: Change From Baseline in Serum Albumin at Week 26 and Week 50

For the determination of serum albumin, blood samples were obtained at designated time points.

Time frame:
Baseline, Week 26, Week 50
Reported as:
Mean · grams/liter
LN Cohort: Change From Baseline in Serum Albumin at Week 26 and Week 50
grams/literLN Cohort: RavulizumabLN Cohort: Placebo
Change at Week 265.14 ± 5.0486.94 ± 5.252
Change at Week 506.44 ± 6.76110.65 ± 5.408
SecondaryIgAN Cohort: Percentage of Participants Meeting the Criteria for Partial Remission

Partial remission was defined as mean proteinuria \<1 g/24 hours, based on two valid 24-hour urine collections obtained within 2 weeks prior to the study visit.

Time frame:
Week 26 and Week 50
Reported as:
Number · percentage of participants
IgAN Cohort: Percentage of Participants Meeting the Criteria for Partial Remission
percentage of participantsIgAN Cohort: RavulizumabIgAN Cohort: Placebo
Week 2626.8 (14.2 to 42.9)18.2 (5.2 to 40.3)
Week 5039.0 (24.2 to 55.5)26.1 (10.2 to 48.4)

Adverse events

Collected over Baseline up to Week 86. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Evaluation Period: LN Cohort - Ravulizumab0/38 (0%)6/38 (15.8%)28/38 (73.7%)
Initial Evaluation Period: LN Cohort - Placebo0/19 (0%)2/19 (10.5%)15/19 (78.9%)
Initial Evaluation Period: IgAN Cohort - Ravulizumab0/43 (0%)1/43 (2.3%)17/43 (39.5%)
Initial Evaluation Period: IgAN Cohort - Placebo0/23 (0%)0/23 (0%)9/23 (39.1%)
Extension Period: LN Cohort - Ravulizumab to Ravulizumab0/36 (0%)6/36 (16.7%)14/36 (38.9%)
Extension Period: LN Cohort - Placebo to Placebo0/18 (0%)2/18 (11.1%)16/18 (88.9%)
Extension Period: IgAN Cohort - Ravulizumab to Ravulizumab0/42 (0%)0/42 (0%)11/42 (26.2%)
Extension Period: IgAN Cohort - Placebo to Ravulizumab0/23 (0%)0/23 (0%)2/23 (8.7%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventInitial Evaluation Period: LN Cohort - RavulizumabInitial Evaluation Period: LN Cohort - PlaceboInitial Evaluation Period: IgAN Cohort - RavulizumabInitial Evaluation Period: IgAN Cohort - PlaceboExtension Period: LN Cohort - Ravulizumab to RavulizumabExtension Period: LN Cohort - Placebo to PlaceboExtension Period: IgAN Cohort - Ravulizumab to RavulizumabExtension Period: IgAN Cohort - Placebo to Ravulizumab
Gastroenteritis norovirusInfections and infestations0/381/190/430/230/361/180/420/23
Acute kidney injuryRenal and urinary disorders0/380/190/430/230/361/180/420/23
COVID-19Infections and infestations0/381/191/430/231/360/180/420/23
Cardiac failure acuteCardiac disorders0/381/190/430/230/360/180/420/23
GastroenteritisInfections and infestations0/381/190/430/230/360/180/420/23
NeutropeniaBlood and lymphatic system disorders0/380/190/430/231/360/180/420/23
BronchitisInfections and infestations0/380/190/430/231/360/180/420/23
Epstein-Barr virus infection reactivationInfections and infestations0/380/190/430/231/360/180/420/23
Soft tissue infectionInfections and infestations0/380/190/430/231/360/180/420/23
Urinary tract infectionInfections and infestations0/380/190/430/231/360/180/420/23
Most frequent other events
Showing 10 of 97
Most frequent other events
EventInitial Evaluation Period: LN Cohort - RavulizumabInitial Evaluation Period: LN Cohort - PlaceboInitial Evaluation Period: IgAN Cohort - RavulizumabInitial Evaluation Period: IgAN Cohort - PlaceboExtension Period: LN Cohort - Ravulizumab to RavulizumabExtension Period: LN Cohort - Placebo to PlaceboExtension Period: IgAN Cohort - Ravulizumab to RavulizumabExtension Period: IgAN Cohort - Placebo to Ravulizumab
CushingoidEndocrine disorders0/383/190/430/230/360/180/420/23
DiarrhoeaGastrointestinal disorders6/382/194/431/231/361/180/420/23
NauseaGastrointestinal disorders6/382/191/432/230/361/180/420/23
Oedema peripheralGeneral disorders3/383/190/432/230/360/180/420/23
CoughRespiratory, thoracic and mediastinal disorders6/382/193/431/231/361/180/420/23
NasopharyngitisInfections and infestations4/380/195/431/233/361/186/420/23
VomitingGastrointestinal disorders5/381/190/430/231/361/180/420/23
HeadacheNervous system disorders5/382/190/430/233/361/183/420/23
RashSkin and subcutaneous tissue disorders5/381/190/433/230/360/180/420/23
Upper respiratory tract infectionInfections and infestations3/382/190/430/231/362/180/420/23

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of the study intervention.

Age, Categorical
Age, Categorical(Participants)LN Cohort: RavulizumabLN Cohort: PlaceboIgAN Cohort: RavulizumabIgAN Cohort: PlaceboTotal
<=18 years00000
Between 18 and 65 years38184322121
>=65 years01012
Sex: Female, Male
Sex: Female, Male(Participants)LN Cohort: RavulizumabLN Cohort: PlaceboIgAN Cohort: RavulizumabIgAN Cohort: PlaceboTotal
Female271522872
Male114211551
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LN Cohort: RavulizumabLN Cohort: PlaceboIgAN Cohort: RavulizumabIgAN Cohort: PlaceboTotal
Hispanic or Latino3511322
Not Hispanic or Latino3114272092
Unknown or Not Reported40509
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LN Cohort: RavulizumabLN Cohort: PlaceboIgAN Cohort: RavulizumabIgAN Cohort: PlaceboTotal
Race — Asian1387735
Race — Black or African American61007
Race — Native Hawaiian or Other Pacific Islander01001
Race — White145311666
Race — Asian, White10001
Race — Not Reported31408
Race — Unknown12003
Race — Other01102
08

Study locations

64 sites
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    South Gate, California 90280, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Orlando, Florida 32835, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    New York, New York 10003, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Columbus, Ohio 43203, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Parkville, 3050, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Québec, Quebec G1R 2J6, Canada
  • Research Site
    Clermont-Ferrand, 63003, France
  • Research Site
    Le Kremlin-Bicêtre, 94270, France
  • Research Site
    Paris, 75020, France
  • Research Site
    Saint-Priest-en-Jarez, 42270, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Torino, 10154, Italy
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    Lodz, 92-213, Poland
  • Research Site
    Anyang-si, 14068, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 134-727, South Korea
  • Research Site
    Seoul, 6591, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Lleida, 25198, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Palma de Mallorca, 07010, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46017, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Kaohsiung City, 833401, Taiwan
  • Research Site
    New Taipei City, 23561, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Edgbaston, B15 2WB, United Kingdom
  • Research Site
    London, SE1 7EH, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Perez Valdivia MA, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25. PubMed 39455063 ↗
  • Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230. PubMed 37528520 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2025, 50 months.

Results were first posted in Jan 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2020
First posted
Sep 25, 2020
StartActual
Jan 19, 2021
Primary completionActual
Mar 26, 2025
CompletionActual
Aug 18, 2025
Results first posted
Jan 22, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04564339
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Jan 19, 2021
Primary completion
Mar 26, 2025
Completion
Aug 18, 2025
Results posted
Jan 22, 2026
Last update
Jan 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion